Last reviewed · How we verify
Investigator's choice of SOC — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Investigator's choice of SOC (Investigator's choice of SOC) — CSPC Megalith Biopharmaceutical Co.,Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Investigator's choice of SOC TARGET | Investigator's choice of SOC | CSPC Megalith Biopharmaceutical Co.,Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Investigator's choice of SOC CI watch — RSS
- Investigator's choice of SOC CI watch — Atom
- Investigator's choice of SOC CI watch — JSON
- Investigator's choice of SOC alone — RSS
Cite this brief
Drug Landscape (2026). Investigator's choice of SOC — Competitive Intelligence Brief. https://druglandscape.com/ci/investigator-s-choice-of-soc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab